Nicox verifies patent extension eligibility at USPTO
22-04-2021
Rob Wilson / Shutterstock.com
A report released by the Australian government has said Australia's extension of term (EoT) scheme for patents in the pharmaceutical industry "has had little effect" on investment and innovation.
An EoT grants pharmaceutical patents an additional five years of protection, after the initial 20 years.
According to the report, released by the Productivity Commission on Tuesday, December 20, the scheme's arrangements have "proven largely illusory".
More than half of new chemical entities approved in Australia have been awarded an extension, and consumers and governments therefore face higher prices for medicines in the extended years.
The report stated: "Rather than compensating firms for being slow to introduce drugs to the Australian market, extensions should only be allowed where the actions of the regulator result in an unreasonable delay."
It added: "Timeframes (of around one year) set by government for the Therapeutic Goods Administration provide a ready benchmark for determining what constitutes a reasonable processing period. EoT should only be granted where the time taken by the regulator exceeds this period."
With the new approach, the government estimates that it would lower the cost of drugs in Australia and save consumers, as well as taxpayers, more than A$250 million ($180 million) per year.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Autralian, EOT, patent, extension, Therapeutic Goods Administration
